Kelch-like ECH-Associated Protein 1 (KEAP1) is a cysteine-rich substrate adaptor protein for the Cullin3-RBX1 E3 ubiquitin ligase complex. KEAP1 is the master repressor of the NRF2 transcription factor, which controls the expression of antioxidant and detoxification genes. Under basal conditions, KEAP1 constitutively targets NRF2 for ubiquitination and proteasomal degradation.[1][2]
In neurodegenerative diseases, KEAP1-NRF2 dysregulation contributes to oxidative stress vulnerability. Oxidative modifications of KEAP1 cysteine residues release NRF2, activating antioxidant gene expression. This system is a major therapeutic target for Alzheimer's disease, Parkinson's disease, and other neurodegenerative conditions.[3]
KEAP1 is a homodimeric protein with five major domains:
NTR (N-terminal region, 1-60): Contains the CUL3-binding motif (IVVM)
BTB/POZ Domain (61-179): Mediates KEAP1 homodimerization and Cul3 binding. The BTB dimer interface brings two KEAP1 monomers together, forming a symmetrical structure that captures NRF2.
IVR (Intervening Region, 180-314): Rich in cysteine residues that sense oxidative stress:
DGR (Double Glycine Repeat) / Kelch Domain (315-598): Six-bladed β-propeller structure that binds to NRF2 and other substrates through the ETGE and DLG motifs. Each blade consists of four antiparallel β-strands.
CTR (C-terminal region, 599-624): Contains additional regulatory cysteines
KEAP1 contains 27 cysteine residues, making it exceptionally sensitive to redox modifications:
| Cysteine | Function | Response to Modification |
|---|---|---|
| C151 | Conformational sensor | Alters KEAP1-Cul3 interaction |
| C273, C288 | Core functional | Blocks NRF2 ubiquitination |
| C226, C613 | Auxiliary sensors | Fine-tunes response |
| C622, C624 | C-terminal sensors | Modulates activity[5] |
KEAP1 controls NRF2 through a "hinge and latch" mechanism:
Under basal conditions, NRF2 has a half-life of ~20 minutes due to KEAP1-mediated degradation.
Upon oxidative stress or electrophilic challenge:
KEAP1 also regulates:
In Alzheimer's disease, KEAP1-NRF2 dysfunction contributes to pathology:
KEAP1 inhibition improves cognitive function and reduces Aβ accumulation in AD mouse models.
In amyotrophic lateral sclerosis:
Electrophilic Compounds:
Non-Electrophilic Inhibitors:
Kensler et al. Keap1-Nrf2 pathway in cellular defense (2007). 2007. ↩︎
Cui et al. Keap1 in neurodegeneration (2022). 2022. ↩︎
[Zhang & Hannink, Keap1 cysteine sensors (2003)](https://doi.org/10.1016/S0092-8674(03). 2003. ↩︎
Dinkova-Kostova AT, et al. Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants. Proc Natl Acad Sci USA. 2002. ↩︎
Yamamoto M, et al. Molecular basis of the Keap1-Nrf2 system. Free Radic Biol Med. 2018. ↩︎
McMahon M, et al. Keap1-dependent turnover of Nrf2: a new paradigm for transcription factor regulation. Toxicol Appl Pharmacol. 2004. ↩︎
Kobayashi A, et al. Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2. Mol Cell Biol. 2004. ↩︎
Ramsey CP, et al. The Nrf2-ARE pathway in the developing mouse brain: a potential therapeutic target for neurodegeneration. Mol Cell Neurosci. 2006. ↩︎
Lastres-Becker I, et al. Frataxin deficiency in a neuronal cell line: altered proteasome activity, oxidative stress and aberrant calcium homeostasis. Neurobiol Dis. 2007. ↩︎
Davies TG, et al. Monoacidic inhibitors of the Kelch-like ECH-associated protein 1: nuclear factor erythroid 2-related factor 2 (KEAP1:NRF2) protein-protein interaction with high cell potency identified by fragment-based drug discovery. J Med Chem. 2016. ↩︎